SCHEMBL25368657

SCHEMBL25368657

CN(C)C(=O)c1ccc(NC(=O)c2csc(C(=O)Nc3cccc(NS(C)(=O)=O)c3)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.47
▸ DHX9 Q08211 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ NAMPT P43490 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543946 0.88 DHX9 (0.53) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL25368280 0.88 DHX9 (0.53) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL25369907 0.87 HPGD (0.56) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL25368447 0.86 HPGD (0.51) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL25368554 0.84 HPGD (0.53) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL25368034 0.84 KMT2A (0.60) HPGDDHX9SMN1; SMN2ALDH1A1LMNA
SCHEMBL25369304 0.83 DHX9 (0.52) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL30544037 0.83 DHX9 (0.52) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL25368128 0.82 EPHX2 (0.48) HPGDKDM4EDHX9TDP1SMN1; SMN2
SCHEMBL25368564 0.82 KDM4E (0.48) HPGDKDM4EDHX9TDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 — — EP claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B HPGD 852/4885KDM4E 1934/4885DHX9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback